Skip to Main Content

Apellis Pharmaceuticals has a good news-bad news problem involving its experimental treatment for geographic atrophy — a chronic eye disease and a leading cause of blindness in older people.

Two large and identically designed Phase 3 clinical trials produced confounding results: One study showed Apellis’ drug, injected into the eye, was a success — significantly slowing the progression of the disease compared to a sham injection. But the drug failed to show a benefit in the other study, albeit narrowly.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment